LAG3 Expression in Triple Negative Breast Cancer

Not Applicable

Recruiting

• Conditions: Triple Negative Breast Cancer; Immune Checkpoint Inhibitor
• Interventions: Procedure: LAG-3 expression / immune checkpoint protein expression

• Registration Number: NCT06259162
• Lead Sponsor: Samsung Medical Center

Brief Summary

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-18
• Status Verified: 2024-02
• Study First Submitted: 2024-02-06
• Study First Submitted QC: 2024-02-06
• Last Update Submitted: 2024-02-06
• Study First Posted: 2024-02-14
• Last Update Posted: 2024-02-14
• Primary Completion: 2025-07-01
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 128

Inclusion Criteria

• Planned neoadjuvant chemotherapy
• Triple negative breast cancer

Exclusion Criteria

• HER2-positive breast cancer
• Hormone receptor positive breast cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
LAG-3 expression/immune checkpoint protein expression evaluation	LAG-3 expression / immune checkpoint protein expression	-

Primary Outcome Measures

Name	Time	Method
LAG-3 expression/immune checkpoint preotein expression	Before chemotherapy, 1 weeks & 3 weeks after chemotherapy, curative surgery	Relationship neoadjuvant chemotherapy plus immune checkpoint inhibitor

Trial Locations

Locations (1)

Ji-Yeon Kim; 🇰🇷 Seoul, Korea, Republic of